Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor

על הניסוי

The purpose of the study is to examine the real-life safety and effectiveness of the novel combination ivacaftor+lumacaftor in eligible patients with cystic fibrosis (CF). All patients with CF were eligible if they were 12 years and older, started ivacaftor+lumacaftor outside of a clinical trial between December 15th 2017 and December 15th 2018 in an accredited CF center in France. Patient followed-up is based on standardized recommendation of the French Cystic Fibrosis Society. Each patient is followed 1 year.

צפו ב-NCT03475381 ב-ClinicalTrials.gov ←

קישורים קשורים